Publication
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugCrizotinibcivic_curation1.00
- geneALKcivic_curation1.00
- geneAREGcivic_curation1.00
- variantALK Amplificationcivic_curation1.00
- variantALK Fusioncivic_curation1.00
- variantALK G1269Acivic_curation1.00
- variantAREG Expressioncivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23344087
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AREG Expression1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Resistance | 2 | accepted | EID781Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions. PMID 23344087 · Kim et al., 2013 · Open in CIViC | civic |
| EGFR AUTOCRINE ACTIVATION1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Resistance | 2 | rejected | EID769Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions. PMID 23344087 · Kim et al., 2013 · Open in CIViC | civic |
| ALK Amplification + ALK Fusion1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID767One patient with ALK-rearranged non-small cell lung cancer and an acquired resistance to crizotinib showed new ALK amplification (4.1 fold increase compared to pre-crizotinib specimen as measured by F… (full text at CIViC) PMID 23344087 · Kim et al., 2013 · Open in CIViC | civic |
| ALK G1269A + ALK Fusion1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID7652 out of 7 patients with an acquired resistance to crizotinib had a G1269A mutation. One of these patients also harbored a L1196M mutation. In vitro follow-up showed reduced crizotinib-induced ALK dep… (full text at CIViC) PMID 23344087 · Kim et al., 2013 · Open in CIViC | civic |
| ALK L1196M + ALK Fusion1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 2 | submitted | EID4036In a stage IV non-small cell lung cancer patient with an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib) and an ALK L1196M co-mutation, ALK L1196M was reported to be refract… (full text at CIViC) PMID 23344087 · Kim et al., 2013 · Open in CIViC | civic |